UK’s NICE Recognizes Cytisine as Key Smoking Cessation Treatment
The 2025 NICE update includes Cytisine as a recommended smoking cessation treatment after its UK launch and a review of clinical evidence.
The 2025 NICE update includes Cytisine as a recommended smoking cessation treatment after its UK launch and a review of clinical evidence.
The 2025 NICE update includes Cytisine as a recommended smoking cessation treatment after its UK launch and a review of clinical evidence.
Read MoreThe WHO has granted Emergency Use Listing for the LC16m8 mpox vaccine, making it the second mpox vaccine to be supported by WHO and the first for children over age 1.
Read MoreThe European Commission has approved Dupixent as an add-on treatment for adults with uncontrolled COPD.
Read MoreThe vaccine was approved for older adults and infants through maternal immunization.Â
Read MoreAstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season.
Read MoreA WHO report conveys the importance of R&D efforts to COVID-19 mRNA vaccines and outlines challenges of inequitable access.
Read MoreWHO advises retaining the current COVID-19 vaccine antigen composition, one that uses a monovalent XBB.1.5 as the COVID-19 vaccine antigen.
Read MoreTwo gene therapies approved by the FDA last week for the treatment of sickle cell disease will have multimillion dollar price tags for patients (and insurers), according to Reuters.
Read MoreHealth Canada granted market authorization for the expanded use of ivacaftor to treat cystic fibrosis in certain children ages 2 months and older.
Read MoreAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) was approved in the EU as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
Read MoreHealth Canada granted market authorization for the expanded use of Trikafta to include children with cystic fibrosis ages 2-5 years who have at least one copy of the F508del mutation in the CFTR gene.
Read MoreA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) plus chemotherapy demonstrated a 42% improvement in central nervous system (CNS) progression-free survival for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) and brain metastases at baseline.
Read MoreThe companies also filed an application with the FDA requesting approval of their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 6 months of age and older.
Read MoreMerck’s investigational drug for chronic cough is one step closer to coming to market after receiving a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read MoreNearly 300 children with cystic fibrosis and two copies of the F508del mutation are now eligible for the first time for a medicine that can treat the underlying cause of their disease.
Read MoreRecipharm’s Vowst therapy is approved to prevent reinfection of C. difficile, which can infect patients with cystic fibrosis and other chronic diseases.
Read MoreThe single-dose antibody drug can be used in babies during their first RSV season and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Read MoreFrequent visits to urban green spaces, such as parks and community gardens, rather than the amount, or views of them from home, may be linked to lower use of certain prescription medications.
Read MoreShanghai became the first city to initiate booster vaccination by inhalation for adults aged 18+ using aerosol drug delivery technology from Aerogen.
Read MoreA randomized trial of nearly 4,000 outpatients with COVID-19 found no benefit from treatment with aspirin or colchicine, according to research presented at ESC Congress 2022.
Read MoreAn expanded ACTIV-6 study will test 600 mcg/kg of ivermectin daily for six days in patients who have had a positive COVID-19 test within the past 10 days, and have at least two symptoms of the illness for no more than seven days.
Read MoreENA Respiratory and the COPD Foundation are partnering to develop an antiviral nasal spray to prevent and reduce incidence and severity of respiratory viral infections in people with chronic lung diseases like COPD.
Read MoreHealth Canada has approved GlaxoSmithKline and Medicago’s Covifenz COVID-19 vaccine, a plant-based virus-like particles, recombinant, adjuvanted vaccine, for adults age 18-64.
Read MoreSanofi and GSK will submit data from both their booster and Phase 3 efficacy trials to the FDA and other international regulatory agencies for authorization of their Sanofi-GSK COVID-19 vaccine.
Read More